Recombinant Human UDP-glucuronosyltransferase 2B17 (UGT2B17)

中文名稱：

人UGT2B17重組蛋白
品名簡(jiǎn)稱：

Recombinant Human UGT2B17 protein
貨號(hào)：

CSB-CF025590HU
說明書：

MSDS Datasheet
規(guī)格：

￥9720
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

純度：

Greater than 85% as determined by SDS-PAGE.
基因名：

UGT2B17
Uniprot No.：

O75795
別名：

(UDPGT 2B17)(UGT2B17)(C19-steroid-specific UDP-glucuronosyltransferase)(C19-steroid-specific UDPGT)
種屬：

Homo sapiens (Human)
蛋白長(zhǎng)度：

Full Length of Mature Protein
來源：

in vitro E.coli expression system
分子量：

64.5 kDa
表達(dá)區(qū)域：

24-530aa
氨基酸序列

GKVLVWPTEYSHWINMKTILEELVQRGHEVIVLTSSASILVNASKSSAIKLEVYPTSLTKNDLEDFFMKMFDRWTYSISKNTFWSYFSQLQELCWEYSDYNIKLCEDAVLNKKLMRKLQESKFDVLLADAVNPCGELLAELLNIPFLYSLRFSVGYTVEKNGGGFLFPPSYVPVVMSELSDQMIFMERIKNMIYMLYFDFWFQAYDLKKWDQFYSEVLGRPTTLFETMGKAEMWLIRTYWDFEFPRPFLPNVDFVGGLHCKPAKPLPKEMEEFVQSSGENGIVVFSLGSMISNMSEESANMIASALAQIPQKVLWRFDGKKPNTLGSNTRLYKWLPQNDLLGHPKTKAFITHGGTNGIYEAIYHGIPMVGIPLFADQHDNIAHMKAKGAALSVDIRTMSSRDLLNALKSVINDPIYKENIMKLSRIHHDQPVKPLDRAVFWIEFVMRHKGAKHLRVAAHNLTWIQYHSLDVIAFLLACVATMIFMITKCCLFCFRKLAKTGKKKKRD
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標(biāo)簽：

N-terminal 10xHis-tagged
產(chǎn)品提供形式：

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
復(fù)溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲(chǔ)存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質(zhì)期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
注意事項(xiàng)：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA：

Please contact us to get it.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Catalyzes the glucuronidation of endogenous steroid hormones such as androgens (epitestosterone, androsterone) and estrogens (estradiol, epiestradiol).
基因功能參考文獻(xiàn)：
1. These data can be used to predict variability in the metabolism of UGT2B17 substrates. PMID: 29602798
2. UGT2B17 was deleted in 64% of children with lymphoblastic malignancy, but in 83% of children with non-lymphoblastic malignancy. UGT2B17 deletion polymorphism may improve the relapse-free rate in children with non-lymphoblastic malignancy. PMID: 27805301
3. Study provides the first evidence of null genotype involvement in UGT2B17 as a risk factor for benign prostatic hyperplasia. PMID: 28882566
4. Chronic lymphocytic leukemia patients with high UGT2B17 and LPL expression have significantly reduced survival. PMID: 26589911
5. UGT2B17 contributes to the in-vitro glucuronidation of arctigenin in liver/intestinal microsomes. PMID: 26407805
6. GC-C-IRMS analysis sensitive to testosterone doping independent of UGT2B17 genotype. PMID: 26198073
7. UGT2B17 mismatch has a negative clinical impact in allogeneic HSCT from HLA-identical sibling donors only when a male donor is used. PMID: 26367234
8. This descriptive study examines correlations between concentrations of tamoxifen's glucuronide metabolites and genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 in 132 patients with estrogen receptor-positive breast cancer under treatment with tamoxifen. PMID: 26176234
9. UGT2B17 deletion polymorphisms are associated with the risk of developing pancreatic cancer in Chinese Han population, especially in the female population. PMID: 26882814
10. UGT2B17-deletion interacting with p16 (+) may modify effects of smoking on TP53-mutations and may further interact with the disruptive TP53-mutations to raise relapse rates among Japanese patients with head and neck squamous cell carcinomas. PMID: 25886176
11. These data suggest that UGT2B17 deletion leads to reduced UGT2B17 activity, and lower BMI in male individuals. This is consistent with the hypothesis that reduced UGT2B17-mediated testosterone excretion results in higher testosterone levels PMID: 25794161
12. The UGT2B17 deletion polymorphism is not associated with tumor risks. PMID: 24802609
13. Structural variants unique to the malignant cell line inactivated: UGT2B17, a gene that inactivates dihydrotestosterone, a known activator of prostate cancer progression. PMID: 23792589
14. Variation in 3HC glucuronidation activity by CYP2A6 caused by UGT2B17 gene deletions did not significantly alter nicotine metabolite ratio in smokers. PMID: 23936477
15. UGT2B17 is a possible target for androgen deprivation therapy of prostate cancer. PMID: 24121496
16. Study indicates that UGT2B17 is not a crucial factor in lung carcinogenesis among Caucasians and shows the importance of investigating such markers in large cohorts from different populations. PMID: 23850147
17. association of the UGT2B17 CNV with AS is particularly interesting given the recent association of this CNV with osteoporosis and the proposed function as it encodes a key enzyme that inhibits androgens PMID: 23927372
18. The prevalence of the UGT2B17 deletion genotype is extremely high in Japanese subjects. PMID: 22887913
19. We observed a significant association between UGT2B17 expressing recipients and UGT2B17 deficient donors with the severity of Acute graft versus host disease. PMID: 22726315
20. The androgen receptor assay may serve as a complement to the urinary testosterone/epitestosterone (T/E) doping test, because this is profoundly influenced by the UGT2B17 deletion polymorphism. PMID: 23294483
21. Report UGT2B17 expression in fetal/adult tissues. PMID: 23223495
22. The present study was aimed to investigate the possible association between 19-base pair (bp) deletion polymorphism of the DHFR gene (rs70991108), null genotype of UGT2B17 as well as the expression level of NGX6 with the risk of breast cancer. PMID: 23053953
23. Data from an in vitro supersome/microsome-based assay suggest that the key steroid-metabolizing enzyme UGT2B17 is inhibited by phenolic dietary substances in red wine and therefore may reduce the rate of testosterone glucuronidation in vivo. PMID: 22958586
24. observed an exclusive involvement of the 2B17 isoform within the UGT protein family in poor-risk chronic lymphocytic leukemia PMID: 23169782
25. Genetic variations in the UGT2B17 gene dramatically affect the pharmacokinetics of MK-7246 in healthy subjects. PMID: 22669291
26. The UGT2B17 Del polymorphism may significantly contribute to prostate cancer susceptibility in men. (Meta-analysis) PMID: 21919858
27. UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women PMID: 21614655
28. we found no evidence of an effect of UGT2B17 CNV on osteoporosis risk in elderly Caucasian women. PMID: 20878390
29. Data show that 698 CNPs loci overlap with known disease-associated or pharmacogenetic-related genes such as CFHR3, CFHR1, GSTTI and UGT2B17. PMID: 21677662
30. data suggest that men have a higher amount of UGT2B17 glucuronidation activity then women PMID: 20810538
31. UGT2B17 expression in prostate cancer is regulated by a novel polymorphism in forkhead boxA1 binding site. PMID: 20628005
32. Overexpression of UGT2B17 is associated with endometrial cancer. PMID: 20554747
33. the association of deletion polymorphism in the UGT2B17 gene with the occurrence of renal disorders on chronic exposure to anabolic androgenic steroids PMID: 20429943
34. Observational study of genetic testing. (HuGE Navigator) PMID: 20192879
35. UGT2B17 deletion polymorphism is associated with a reduced rate of NNAL detoxification in vivo and may increase individual susceptibility to tobacco-related cancers. PMID: 16220109
36. The UGT2B17 polymorphism is strongly associated with the bimodal distribution of testosterone excretion and also with the large difference in testosterone excretion between Koreans and Swedes. PMID: 16332934
37. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 is associated with prostate cancer PMID: 16896035
38. The UGT2B17 deletion polymorphism is associated with prostate cancer risk. PMID: 17387331
39. association of the UGT2B17 deletion with increased lung adenocarcinoma in women is consistent with its association with decreased 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation rates in women PMID: 17416778
40. results suggest that the HSD3B1 N367T and UGT2B17 null polymorphisms may modify the risk of prostate cancer, particularly among men with a family history of the disease PMID: 17826523
41. These findings show that the UGT2B17 deletion polymorphism is not associated with prostate cancer risk in Caucasians. PMID: 17935910
42. The UGT2B17 deletion polymorphism does not play a major role in prostate cancer susceptibility as previously indicated. PMID: 18247404
43. UGT2B17 ia a primary androgen-regulated genes and androgen receptor is required for basal expression and androgen-regulated expression. PMID: 18302198
44. Diversity was unusually high, with evidence of balancing selection in Europe. In contrast, diversity was low in East Asia where a single haplotype predominated, suggesting positive selection for the deletion in this part of the world PMID: 18760392
45. Genome-wide copy-number variation identified a susceptibility gene, UGT2B17, for osteoporosis. PMID: 18992858
46. In pubertal boys, a common homozygous deletion in the UGT2B17 gene strongly affected urinary excretion pattern of androgen metabolites but did not influence circulating androgen levels. PMID: 19088161
47. Large testosterone excretion is associated with a deletion polymorphism of the UGT2B17 gene. This polymorphism decreases T/E ratio level. PMID: 19224506
48. Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 PMID: 19572376
顯示更多

收起更多
亞細(xì)胞定位：

Endoplasmic reticulum membrane; Single-pass membrane protein.
蛋白家族：

UDP-glycosyltransferase family
組織特異性：

Expressed in various tissues including the liver, kidney, testis, uterus, placenta, mammary gland, adrenal gland, skin and prostate.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 12547

OMIM: 601903

KEGG: hsa:7367

STRING: 9606.ENSP00000320401

UniGene: Hs.575083